triazoles has been researched along with ketorolac in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maruta, H; Nguyen, BCQ; Shahinozzaman, MD; Takahashi, H; Tawata, S; Uto, Y | 1 |
| Adrian, TE; Albawardi, A; Almarzooqi, S; Haneefa, S; Hennig, R; Imbaraj, E; Maruta, H; Nemmar, A; Subramanya, S; Zaaba, NE | 1 |
| Ahmed, S; Emran, R; Shahinozzaman, M; Tawata, S | 1 |
4 other study(ies) available for triazoles and ketorolac
| Article | Year |
|---|---|
News drugs and dosage forms.
Topics: Anti-HIV Agents; Antifungal Agents; Atazanavir Sulfate; Drug Combinations; Humans; Ketorolac; Oligopeptides; Phenylephrine; Pyridines; Testosterone; Triazoles | 2014 |
1,2,3-Triazolyl ester of Ketorolac: A "Click Chemistry"-based highly potent PAK1-blocking cancer-killer.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Click Chemistry; Cyclooxygenase 2 Inhibitors; Esters; Humans; Ketorolac; p21-Activated Kinases; Protein Kinase Inhibitors; Signal Transduction; Triazoles | 2017 |
1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice.
Topics: Animals; Body Weight; Cell Line, Tumor; Cell Proliferation; Esters; Hemodynamics; Humans; Inhibitory Concentration 50; Ketorolac; Mice; Mice, Nude; Neoplasm Invasiveness; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1.
Topics: 3T3 Cells; Allosteric Regulation; Animals; Esters; Ketorolac; Mice; Models, Molecular; Molecular Dynamics Simulation; Oncogenes; p21-Activated Kinases; Protein Conformation; Triazoles | 2021 |